<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957305</url>
  </required_header>
  <id_info>
    <org_study_id>160309</org_study_id>
    <nct_id>NCT02957305</nct_id>
  </id_info>
  <brief_title>Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage</brief_title>
  <acronym>MISO200</acronym>
  <official_title>Comparison Between 400 µg or 200 µg of Misoprostol for Cervical Dilatation in 1st Trimester Miscarriage - A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Local current protocol for cervical ripening in 1st trimester miscarriage recommends 400 µg
      of misoprostol intravaginally 3 hours before uterine evacuation. This regime has been
      recommended by some international guidelines . So far, there are no recent studies comparing
      cervical dilatation between 400 µg of misoprostol and a reduced dose (e.g., 200 µg). If
      cervical ripening is similar between these two regimens, costs reductions and lower side
      effects may be issued without losing quality of cervix dilatation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Miscarriage is defined by the World Health Organization as the interruption of the pregnancy
      up to 20-23 weeks, or the products of pregnancy weighting less than 500 grams (1). Nearly 15%
      of known pregnancies end in miscarriage, especially in the first 12 weeks. Estimates indicate
      that 68000 women die worldwide each year, as a result of unsafe abortions. Abortions are the
      major cause of maternal death, particularly in Latin America and the Caribbean. In cases of
      retained and incomplete abortions, uterine emptying is recommended. In the first trimester of
      pregnancy, either pharmacological or surgical procedure is accepted according to
      international guidelines.

      Pharmacological treatment for uterine evacuation includes the administration of mifepristone
      and misoprostol or misoprostol alone. Nevertheless, surgical methods has been shown a greater
      acceptability and patient satisfaction due to a reduced incidence of adverse effects.
      Currently, Manual Intrauterine Aspiration (MIUA) is the technique recommended by the
      Brazilian Ministry of Health, and the Brazilian Federation of Gynecology and Obstetrics.

      MIUA should be performed after cervical ripening. This pre-surgical procedure makes the
      procedure safer and more effective. In Brazil, misoprostol is the most suitable drug to be
      used in these cases because of its efficacy, easy of use, low cost, stability at room
      temperature and availability. Misoprostol is a synthetic prostaglandin E1 analogue and can be
      administered by oral, sublingual, buccal, rectal and vaginal routes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Required cervix dilatation to appropriate intrauterine suction</measure>
    <time_frame>1 year</time_frame>
    <description>Cervical permeability (&gt;= 8mm of dilation).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Miscarriage, Incomplete</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Misoprostol 400 µg 3 hours before intrauterine suction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Misoprostol 200 µg 3 hours before intrauterine suction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 400 µg</intervention_name>
    <description>Evaluate the required cervix dilation in the moment of the intrauterne suction</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Misoprostol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 200 µg</intervention_name>
    <description>Evaluate the required cervix dilation in the moment of the intrauterne suction</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Misoprostol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients admitted at the Gynecological emergency Unit at Hospital de Clínicas de
             Porto Alegre scheduled for uterine evacuation with &lt;12 weeks of gestation.

        Exclusion Criteria:

          -  patients who do not wish to participate in the project;

          -  patients with ectopic pregnancy;

          -  patients with comorbidities (heart failure congestive, chronic obstructive pulmonary
             disease);

          -  patients with hypovolemic shock;

          -  patients with cervical incompetence;

          -  patients with infected miscarriage/abortion (presence of fever, pus from the cervix,
             leukocytosis [&gt; 14000]);

          -  patients with twin pregnancy;

          -  patients with Marfan syndrome;

          -  patients allergic to misoprostol;

          -  patients with coagulopathy;

          -  patients with opening of cervical internal os (4 mm of dilatation at the time of
             consultation);

          -  patients with previous surgery of the cervix (conization);

          -  patients with concomitant use of IUDs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo F Ricardo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCPA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo F Ricardo, MD, PhD</last_name>
    <email>rsavaris@hcpa.edu.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>HCPA</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RICARDO SAVARIS, PHD</last_name>
      <email>rsavaris@hcpa.edu.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Kapp N, Lohr PA, Ngo TD, Hayes JL. Cervical preparation for first trimester surgical abortion. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007207. doi: 10.1002/14651858.CD007207.pub2. Review.</citation>
    <PMID>20166091</PMID>
  </results_reference>
  <results_reference>
    <citation>Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women's health: a review. Obstet Gynecol. 2002 Feb;99(2):316-32. Review.</citation>
    <PMID>11814515</PMID>
  </results_reference>
  <results_reference>
    <citation>Marret H, Simon E, Beucher G, Dreyfus M, Gaudineau A, Vayssière C, Lesavre M, Pluchon M, Winer N, Fernandez H, Aubert J, Bejan-Angoulvant T, Jonville-Bera AP, Clouqueur E, Houfflin-Debarge V, Garrigue A, Pierre F; Collège national des gynécologues obstétriciens français. Overview and expert assessment of off-label use of misoprostol in obstetrics and gynaecology: review and report by the Collège national des gynécologues obstétriciens français. Eur J Obstet Gynecol Reprod Biol. 2015 Apr;187:80-4. doi: 10.1016/j.ejogrb.2015.01.018. Epub 2015 Jan 31. Review.</citation>
    <PMID>25701235</PMID>
  </results_reference>
  <results_reference>
    <citation>National Collaborating Centre for Women's and Children's Health (UK). Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage. London: RCOG; 2012 Dec.</citation>
    <PMID>23638497</PMID>
  </results_reference>
  <results_reference>
    <citation>ACOG Committee Opinion. American College of Obstetrician and Gynecologist. ACOG Committee Opinion. Number 283, May 2003. New U.S. Food and Drug Administration labeling on Cytotec (misoprostol) use and pregnancy. Obstet Gynecol. 2003 May;101(5 Pt 1):1049-50.</citation>
    <PMID>12738178</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet. 2013 May;121(2):186-9. doi: 10.1016/j.ijgo.2012.12.009. Epub 2013 Feb 19.</citation>
    <PMID>23433680</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Clinicas de Porto Alegre</investigator_affiliation>
    <investigator_full_name>Ricardo Francalacci Savaris</investigator_full_name>
    <investigator_title>Head of the Gynecologic Emergency Unit</investigator_title>
  </responsible_party>
  <keyword>misoprostol</keyword>
  <keyword>miscarriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

